You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥(00013.HK)2025年上半年應占淨收益4.55億美元
格隆匯 08-07 19:16

格隆匯8月7日丨和黃醫藥(00013.HK)公吿,截至2025年6月30日止6個月收入為2.777億美元,而截至2024年6月30日止6個月為3.057億美元。截至2025年6月30日止6個月和黃醫藥應占淨收益為4.55億美元,而截至2024年6月30日止6個月則為2580萬美元。和黃醫藥應占淨收益為每股普通股0.53美元/每份ADS2.65美元(2024年上半年:每股普通股0.03美元/每份ADS0.15美元)。

2025年上半年和黃醫藥應占淨收益為4.55億美元(2024年上半年:2,580萬美元),於2025年6月30日的現金餘額為13.6億美元,主要得益於出售一家非核心合資公司的部分股權後4.163億美元的税後出售收益及出售款項。

2025年6月30日,沃瑞®(ORPATHYS®,賽沃替尼/savolitinib)的第三項肺癌適應症於中國獲批,即與泰瑞®(TAGRISSO®,奧希替尼/osimertinib)的聯合療法用於治療經EGFR抑制劑治療後進展的伴MET擴增的EGFR突變非小細胞肺癌患者,有望參與今年年底的國家醫保目錄談判。該聯合療法為相當一部分(約佔30%)的此類非小細胞肺癌患者提供了唯一一種口服、去化療的治療選擇。此項批准觸發一項來自阿斯利康的1,100萬美元的里程碑付款,阿斯利康同時負責沃瑞®和泰瑞®的銷售。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account